Premium
Orally active angiotensin‐converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension.
Author(s) -
Brunner HR,
Gavras H,
Waeber B,
Turini GA,
McKinstry DN,
Vukovich RA,
Gavras I
Publication year - 1979
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1979.tb04692.x
Subject(s) - captopril , essential hypertension , plasma renin activity , diuretic , medicine , angiotensin converting enzyme , aldosterone , endocrinology , ambulatory , pharmacology , enzyme inhibitor , chemotherapy , ace inhibitor , renin–angiotensin system , urology , blood pressure , enzyme , chemistry , biochemistry
1 Captopril (SQ14,225), an orally active inhibitor of angiotensin‐ converting enzyme, was administered to nine patients with essential hypertension. Plasma renin activity (PRA) was low in four, 'normal' in three and high in two patients. 2 In the hospital, captopril alone induced a significant drop in BP from 165 +/‐ 6/106 +/‐ 2 to 140 +/‐ 5/90 +/‐ 1 mmHb (P less than 0.001). PRA increased concomitantly (P less than 0.05), whereas plasma‐converting enzyme activity (P less than 0.005) and plasma aldosterone (P less than 0.05) were reduced. 3 Six patients underwent chronic ambulatory therapy with captopril for a mean of 16 +/‐ 3 weeks. After discharge from the hospital, BP remained normalized but in five out of six patients this required additional diuretic therapy. 4 The results suggest that captopril alone or combined with diuretic therapy provides a new, efficient and well tolerated tool to treat patients with essential hypertension independently of their PRA level. It may turn out to be more effective in lowering BP than beta‐adrenoceptor‐blocking agents.